Lumida
/CRMD
⌘K
CorMedix Inc

CorMedix Inc

CRMD
$7.83USD↓-1.70%-0.13 today

MARKET CAP

609.9M

P/E (TTM)

3.6x

FWD P/E

—

DAY RANGE

$8 – $8

52W RANGE

$6
$13

AI Summary

Stalk
Sell NowMedium

CRMD is entrenched in a Stage 4 decline with a clear sequence of lower highs and lower lows. Short-term trend and EMAs are sloping downward, and price is extended below moving averages without signs of exhaustion. The medium-term bias remains bearish, unsupported by any mean-reversion eligibility, justifying an immediate sell initiation into resistance at the declining EMA regime.

  • ↑Q2 revenue $101.9M up 100% YoY; EPS $0.29 beat $0.25 consensus; EBITDA guidance raised to $125–140M
  • ↑Median analyst price target $15 signals ~96% upside from current levels
  • ↓Significant price swings highlight elevated volatility risk
Full analysis →

Buying

3

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY6.32 M49.64 M+356.54 K+22.5%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL358.11 K2.81 M+-356.90 K-42.1%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

BUYNEW202.37 K1.59 M+202.37 K+0.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

SELL151.44 K1.19 M+-83.25 K-25.4%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL67.42 K515.05 K+-48.55 K-32.4%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUY53.80 K365.57 K+26.90 K+16.9%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL36.32 K285.08 K+-3.71 K+4.9%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL195.001.53 K+-515.00-68.2%0.00%